Before revision: Eftilagimod alpha URL development code IMP321 ; trade name ImmuFact ) is a large molecule cancer drug being developed by the clinical stage biotechnology company Immutep.
After revision: Eftilagimod alpha URL development code IMP321 or efti ) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep.